Our improved α-synuclein seed amplification assay dramatically reduces the time needed to diagnose Parkinson’s disease while maintaining the high-performance standards associated with previous α-synuclein seed assays, supporting the clinical utility of this assay for Parkinson’s disease diagnosis. https://doi.org/10.1002/acn3.51280
In response to behaviorally salient stimuli, dopamine (DA) neuronsfire in bursts. These data show that the LDTg is critical to normal DA function,and thus, pathology within this region may lead to aberrant DAsignaling. http://www.pnas.orgcgidoi10.1073pnas.0510715103
Neurodegenerative diseases, Parkinson disease among them, set challenges to modern societies both in terms of premature deaths and resources spent on treatment of the diseases. At that, preventive care and early diagnostics in particular are potential directions towards higher economic efficiency of healthcare interventions in this area. https://doi.org/10.3897/popecon.4.e59949
Sleep Disorders (SDs) precede motor symptoms of Parkinson’s disease (PD), suggesting an early effect of disease processes on sleep control neurons. These nucleus-specific differential effects suggest previously unappreciated, mechanistic underpinnings of SDs’ prodromal PD appearance in PD, and wehypothesize that in the prodromal phase of PD, the early form of α-synuclein compromises sleep-control neurons. https://doi.org/10.21203/rs.3.rs-134060/v1
Neuronal lesions in Parkinson’s disease (PD) are commonly associated with α-synuclein (α-Syn)-induced cell damage that are present both in the central and peripheral nervous systems of patients, with the enteric nervous system also being especially vulnerable. Here, we bring together evidence that the development and presence of PD depends on specific sets of interlinking factors